Literature DB >> 9930070

MUC1 (episialin) expression in non-small cell lung cancer is independent of EGFR and c-erbB-2 expression and correlates with poor survival in node positive patients.

F Guddo1, A Giatromanolaki, M I Koukourakis, C Reina, A M Vignola, G Chlouverakis, J Hilkens, K C Gatter, A L Harris, G Bonsignore.   

Abstract

AIM: To examine tumour samples immunohistochemically for MUC1 (episialin), epidermal growth factor receptor (EGFR), and c-erbB-2, since the disruption of the cell-cell adhesion system by MUC1 and the c-erbB oncoprotein family is known to be important in the development of metastasis in human cancers.
METHODS: 93 tumour samples from patients with early stage non-small cell lung cancer treated with surgery alone were examined for episialin, EGFR, and c-erbB-2.
RESULTS: Episialin depolarised expression did not correlate with any of the histopathological variables examined (T,N stage, grade, histology, Ki67 proliferation index). No correlation was observed between episialin and EGFR or c-erbB-2 expression. Survival analysis showed that episialin depolarised expression correlated with poor prognosis (p = 0.003), especially in squamous cell cases (p = 0.0003). Episialin expression defined a group of patients with poor prognosis in the node positive category (p = 0.003). In multivariate analysis episialin was the most significant independent prognostic factor (p = 0.007), followed by N stage (p = 0.04).
CONCLUSIONS: Depolarised expression of episialin is associated with poor outcome in early stage non-small cell lung cancer. Despite the similar activity on the cadherin cell-cell adhesion system, the expression of episialin and c-erbB oncoproteins is likely to be activated within different pathogenic pathways.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9930070      PMCID: PMC500903          DOI: 10.1136/jcp.51.9.667

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  25 in total

Review 1.  Current approaches to targeting cancer using antiangiogenesis therapies.

Authors:  P A Scott; A L Harris
Journal:  Cancer Treat Rev       Date:  1994-10       Impact factor: 12.111

2.  Ki-67 immunostaining and survival in operable lung cancer.

Authors:  M F Tungekar; K C Gatter; M S Dunnill; D Y Mason
Journal:  Histopathology       Date:  1991-12       Impact factor: 5.087

Review 3.  Antiangiogenesis as a strategy for antimetastasis.

Authors:  P A D'Amore
Journal:  Semin Thromb Hemost       Date:  1988-01       Impact factor: 4.180

4.  Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells.

Authors:  D L Barnd; M S Lan; R S Metzgar; O J Finn
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

5.  Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells.

Authors:  K R Jerome; D L Barnd; K M Bendt; C M Boyer; J Taylor-Papadimitriou; I F McKenzie; R C Bast; O J Finn
Journal:  Cancer Res       Date:  1991-06-01       Impact factor: 12.701

6.  c-erbB-2 gene product directly associates with beta-catenin and plakoglobin.

Authors:  Y Kanai; A Ochiai; T Shibata; T Oyama; S Ushijima; S Akimoto; S Hirohashi
Journal:  Biochem Biophys Res Commun       Date:  1995-03-28       Impact factor: 3.575

7.  Monoclonal antibodies against human milk-fat globule membranes detecting differentiation antigens of the mammary gland and its tumors.

Authors:  J Hilkens; F Buijs; J Hilgers; P Hageman; J Calafat; A Sonnenberg; M van der Valk
Journal:  Int J Cancer       Date:  1984-08-15       Impact factor: 7.396

Review 8.  The cadherins: cell-cell adhesion molecules controlling animal morphogenesis.

Authors:  M Takeichi
Journal:  Development       Date:  1988-04       Impact factor: 6.868

9.  Epidermal growth factor receptors in non-small cell lung cancer.

Authors:  D Veale; T Ashcroft; C Marsh; G J Gibson; A L Harris
Journal:  Br J Cancer       Date:  1987-05       Impact factor: 7.640

10.  Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components.

Authors:  J Wesseling; S W van der Valk; H L Vos; A Sonnenberg; J Hilkens
Journal:  J Cell Biol       Date:  1995-04       Impact factor: 10.539

View more
  38 in total

Review 1.  Mucins and toll-like receptors: kith and kin in infection and cancer.

Authors:  Shikha Tarang; Sushil Kumar; Surinder K Batra
Journal:  Cancer Lett       Date:  2012-02-03       Impact factor: 8.679

Review 2.  Glycosylation alterations in lung and brain cancer.

Authors:  Hassan Lemjabbar-Alaoui; Andrew McKinney; Yi-Wei Yang; Vy M Tran; Joanna J Phillips
Journal:  Adv Cancer Res       Date:  2015-02-07       Impact factor: 6.242

3.  Transmembrane mucins as novel therapeutic targets.

Authors:  Pamela E Constantinou; Brian P Danysh; Neeraja Dharmaraj; Daniel D Carson
Journal:  Expert Rev Endocrinol Metab       Date:  2011-11

4.  Muc1 knockout potentiates murine lung carcinogenesis involving an epiregulin-mediated EGFR activation feedback loop.

Authors:  Xiuling Xu; Wenshu Chen; Shuguang Leng; Mabel T Padilla; Bryanna Saxton; Julie Hutt; Mathewos Tessema; Kosuke Kato; Kwang Chul Kim; Steven A Belinsky; Yong Lin
Journal:  Carcinogenesis       Date:  2017-06-01       Impact factor: 4.944

5.  MUC1 in macrophage: contributions to cigarette smoke-induced lung cancer.

Authors:  Xiuling Xu; Mabel T Padilla; Bilan Li; Alexandria Wells; Kosuke Kato; Carmen Tellez; Steven A Belinsky; Kwang Chul Kim; Yong Lin
Journal:  Cancer Res       Date:  2013-11-26       Impact factor: 12.701

Review 6.  Host response in tumor diagnosis and prognosis: importance of immunologists and pathologists alliance.

Authors:  Olivera J Finn
Journal:  Exp Mol Pathol       Date:  2012-10-23       Impact factor: 3.362

Review 7.  Current status of mucins in the diagnosis and therapy of cancer.

Authors:  Satyanarayana Rachagani; Maria P Torres; Nicolas Moniaux; Surinder K Batra
Journal:  Biofactors       Date:  2009 Nov-Dec       Impact factor: 6.113

8.  MUC1-associated proliferation signature predicts outcomes in lung adenocarcinoma patients.

Authors:  Dhara M MacDermed; Nikolai N Khodarev; Sean P Pitroda; Darrin C Edwards; Charles A Pelizzari; Lei Huang; Donald W Kufe; Ralph R Weichselbaum
Journal:  BMC Med Genomics       Date:  2010-05-06       Impact factor: 3.063

Review 9.  MUC1 and MUC2 in pancreatic neoplasia.

Authors:  E Levi; D S Klimstra; A Andea; O Basturk; N V Adsay
Journal:  J Clin Pathol       Date:  2004-05       Impact factor: 3.411

10.  A signaling pathway consisting of miR-551b, catalase and MUC1 contributes to acquired apoptosis resistance and chemoresistance.

Authors:  Xiuling Xu; Alexandria Wells; Mabel T Padilla; Kosuke Kato; Kwang Chul Kim; Yong Lin
Journal:  Carcinogenesis       Date:  2014-08-01       Impact factor: 4.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.